" class="no-js "lang="en-US"> OPEN Health Acquires Medical Communications Agency Spirit - Medtech Alert
Monday, April 15, 2024

OPEN Health Acquires Medical Communications Agency Spirit

OPEN Health has today announced the acquisition of North West UK-based medical communications agency Spirit. Integrating the Spirit business with the OPEN Health Group further strengthens our ability to offer our global Medical Affairs audiences a broad range of services, including high-quality scientific communications.

In terms of scale, the acquisition means that OPEN Health now consists of >850 people in 15 locations across 6 different countries, namely the USA, the UK, the NetherlandsGermanyIndia, and China.

Iona Fleming, Managing Director of Spirit, said, “Over the past 15 years, we have proudly grown Spirit to an 80-person Medical Affairs agency – delivering a broad range of scientific communications globally. In joining OPEN Health, we are significantly expanding our geographical reach and will be able to provide a wider range of integrated services to our Medical Affairs and HEOR clients. We very much look forward to working with the OPEN Health management and Amulet teams to contribute to the long-term growth of OPEN Health.”

Rob Barker, Chief Executive Officer at OPEN Health, commented, “We are delighted to welcome Spirit into the OPEN Health family. This strategic acquisition will enhance our global Medical Affairs resources, further supporting our unique offerings and opportunities for innovation to support industry change and growth.”

OPEN Health is a portfolio company of Amulet Capital Partners LP, a US-based private equity firm focused exclusively on the healthcare sector. 

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more